Response to Peptide Receptor Radionuclide Therapy in Pheocromocytomas and Paragangliomas: A Systematic Review and Meta-Analysis.
177Lu-DOTATATE
90Y-DOTATOC
PRRT
meta-analysis
neuroendocrine tumors
paragangliomas
pheocromocytomas
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
13 Feb 2023
13 Feb 2023
Historique:
received:
11
11
2022
revised:
03
01
2023
accepted:
08
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC showed efficacy in the metastatic setting of pheocromocytomas (PCCs) and paragangliomas (PGLs) where no standard therapies have been established. A search of peer-reviewed and English articles reporting on 177Lu-DOTATATE and 90Y-DOTATOC efficacy was performed through Medline and Scopus. A subsequent meta-analysis was performed to evaluate the pooled effect size on disease control rate (DCR) with PRRT. Secondary endpoints were description of patients' genetic characteristics, hematologic toxicity, and time-to-outcome. The pooled effect was estimated with both a mixed-effects model and a random-effects model. Twelve studies met the criteria for this meta-analysis: ten with 177Lu- and two with 90Y-PRRTs (213 patients). The largest one included 46 patients. Median ages ranged from 32.5 to 60.4 years. When reported, mutations of SDHB were the most frequent genetic alterations. The pooled DCRs were 0.83 (95% CI: 0.75-0.88) and 0.76 (95% CI: 0.56-0.89) for 177Lu- and 90Y-PRRT, respectively. The pooled DCR for PRRT was 0.81 (95% CI: 0.74-0.87). We report an updated and solid estimate of DCR achieved with 177Lu- and 90Y-PRRT in PCCs and PGLs, showing that these therapies can be considered in the multidisciplinary treatment of PCCs and PGLs as alternatives to I-131 MIBG and chemotherapy.
Sections du résumé
INTRODUCTION
BACKGROUND
Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC showed efficacy in the metastatic setting of pheocromocytomas (PCCs) and paragangliomas (PGLs) where no standard therapies have been established.
BACKGROUND
BACKGROUND
A search of peer-reviewed and English articles reporting on 177Lu-DOTATATE and 90Y-DOTATOC efficacy was performed through Medline and Scopus. A subsequent meta-analysis was performed to evaluate the pooled effect size on disease control rate (DCR) with PRRT. Secondary endpoints were description of patients' genetic characteristics, hematologic toxicity, and time-to-outcome. The pooled effect was estimated with both a mixed-effects model and a random-effects model.
RESULTS
RESULTS
Twelve studies met the criteria for this meta-analysis: ten with 177Lu- and two with 90Y-PRRTs (213 patients). The largest one included 46 patients. Median ages ranged from 32.5 to 60.4 years. When reported, mutations of SDHB were the most frequent genetic alterations. The pooled DCRs were 0.83 (95% CI: 0.75-0.88) and 0.76 (95% CI: 0.56-0.89) for 177Lu- and 90Y-PRRT, respectively. The pooled DCR for PRRT was 0.81 (95% CI: 0.74-0.87).
CONCLUSIONS
CONCLUSIONS
We report an updated and solid estimate of DCR achieved with 177Lu- and 90Y-PRRT in PCCs and PGLs, showing that these therapies can be considered in the multidisciplinary treatment of PCCs and PGLs as alternatives to I-131 MIBG and chemotherapy.
Identifiants
pubmed: 36836029
pii: jcm12041494
doi: 10.3390/jcm12041494
pmc: PMC9964778
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Endocrinol Metab (Seoul). 2017 Jun;32(2):152-161
pubmed: 28685506
J Clin Oncol. 2011 Jun 10;29(17):2416-23
pubmed: 21555692
Cancers (Basel). 2022 Jan 25;14(3):
pubmed: 35158861
BMC Med Res Methodol. 2014 Dec 19;14:135
pubmed: 25524443
Clin Nucl Med. 2017 Jul;42(7):525-529
pubmed: 28481789
J Clin Endocrinol Metab. 2021 Apr 23;106(5):e1937-e1952
pubmed: 33462603
Nucl Med Commun. 2018 Aug;39(8):789-796
pubmed: 29912750
Med Oncol. 2016 May;33(5):47
pubmed: 27059363
J Nucl Med. 2006 Oct;47(10):1599-606
pubmed: 17015894
Lancet. 2005 Aug 20-26;366(9486):665-75
pubmed: 16112304
Endocr Connect. 2020 Oct;9(9):864-873
pubmed: 32784267
Clin Endocrinol (Oxf). 2014 Apr;80(4):487-501
pubmed: 24118038
J Clin Endocrinol Metab. 2019 Apr 1;104(4):1336-1344
pubmed: 30566620
Clin Nucl Med. 2017 Jun;42(6):436-443
pubmed: 28263217
Endocr Relat Cancer. 2007 Sep;14(3):569-85
pubmed: 17914089
Cancers (Basel). 2019 Jun 28;11(7):
pubmed: 31261748
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
ANZ J Surg. 2003 Sep;73(9):712-6
pubmed: 12956787
Clin Endocrinol (Oxf). 2019 Dec;91(6):718-727
pubmed: 31569282
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2112-2137
pubmed: 31254038
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Clin Med. 2019 Jun 30;8(7):
pubmed: 31262070
Clin Endocrinol (Oxf). 2014 Nov;81(5):642-51
pubmed: 25041164
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):970-988
pubmed: 29497803
Endocr Pathol. 2017 Sep;28(3):213-227
pubmed: 28477311
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Cancer. 2012 Dec 15;118(24):6162-70
pubmed: 22736481
Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022 Jan-Feb;41(1):55-65
pubmed: 34920969
ESMO Open. 2021 Aug;6(4):100171
pubmed: 34139487
Br J Cancer. 2019 Jun;120(12):1113-1119
pubmed: 31105270
J Clin Endocrinol Metab. 2007 Oct;92(10):3822-8
pubmed: 17652212
Endocr Relat Cancer. 2007 Sep;14(3):587-99
pubmed: 17914090
Tumori. 2022 Dec;108(6):526-540
pubmed: 35593402
Endocrine. 2011 Dec;40(3):354-65
pubmed: 22038451
N Engl J Med. 2019 Aug 8;381(6):552-565
pubmed: 31390501